tetano
Editor, Senior Moderator
Nat Commun
. 2021 Aug 6;12(1):4740.
doi: 10.1038/s41467-021-24979-9.
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Natalia Ortega[SUP] #[/SUP][SUP] 1 [/SUP], Marta Ribes[SUP] #[/SUP][SUP] 1 [/SUP], Marta Vidal[SUP] 1 [/SUP], Rocío Rubio[SUP] 1 [/SUP], Ruth Aguilar[SUP] 1 [/SUP], Sarah Williams[SUP] 1 [/SUP], Diana Barrios[SUP] 1 [/SUP], Selena Alonso[SUP] 1 [/SUP], Pablo Hernández-Luis[SUP] 2 3 [/SUP], Robert A Mitchell[SUP] 1 [/SUP], Chenjerai Jairoce[SUP] 1 4 [/SUP], Angeline Cruz[SUP] 1 [/SUP], Alfons Jimenez[SUP] 1 5 [/SUP], Rebeca Santano[SUP] 1 [/SUP], Susana Méndez[SUP] 1 [/SUP], Montserrat Lamoglia[SUP] 1 6 [/SUP], Neus Rosell[SUP] 1 [/SUP], Anna Llupià[SUP] 1 7 [/SUP], Laura Puyol[SUP] 1 [/SUP], Jordi Chi[SUP] 1 [/SUP], Natalia Rodrigo Melero[SUP] 8 [/SUP], Daniel Parras[SUP] 2 [/SUP], Pau Serra[SUP] 2 [/SUP], Edwards Pradenas[SUP] 9 [/SUP], Benjamin Trinité[SUP] 9 [/SUP], Julià Blanco[SUP] 9 10 [/SUP], Alfredo Mayor[SUP] 1 4 5 [/SUP], Sonia Barroso[SUP] 11 [/SUP], Pilar Varela[SUP] 11 [/SUP], Anna Vilella[SUP] 1 5 [/SUP], Antoni Trilla[SUP] 1 5 12 [/SUP], Pere Santamaria[SUP] 7 13 14 [/SUP], Carlo Carolis[SUP] 8 [/SUP], Marta Tortajada[SUP] 11 [/SUP], Luis Izquierdo[SUP] 1 [/SUP], Ana Angulo[SUP] 2 3 [/SUP], Pablo Engel[SUP] 2 3 [/SUP], Alberto L García-Basteiro[SUP] 1 4 15 [/SUP], Gemma Moncunill[SUP] 16 [/SUP], Carlota Dobaño[SUP] 17 18 [/SUP]
Affiliations
Abstract
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.
. 2021 Aug 6;12(1):4740.
doi: 10.1038/s41467-021-24979-9.
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Natalia Ortega[SUP] #[/SUP][SUP] 1 [/SUP], Marta Ribes[SUP] #[/SUP][SUP] 1 [/SUP], Marta Vidal[SUP] 1 [/SUP], Rocío Rubio[SUP] 1 [/SUP], Ruth Aguilar[SUP] 1 [/SUP], Sarah Williams[SUP] 1 [/SUP], Diana Barrios[SUP] 1 [/SUP], Selena Alonso[SUP] 1 [/SUP], Pablo Hernández-Luis[SUP] 2 3 [/SUP], Robert A Mitchell[SUP] 1 [/SUP], Chenjerai Jairoce[SUP] 1 4 [/SUP], Angeline Cruz[SUP] 1 [/SUP], Alfons Jimenez[SUP] 1 5 [/SUP], Rebeca Santano[SUP] 1 [/SUP], Susana Méndez[SUP] 1 [/SUP], Montserrat Lamoglia[SUP] 1 6 [/SUP], Neus Rosell[SUP] 1 [/SUP], Anna Llupià[SUP] 1 7 [/SUP], Laura Puyol[SUP] 1 [/SUP], Jordi Chi[SUP] 1 [/SUP], Natalia Rodrigo Melero[SUP] 8 [/SUP], Daniel Parras[SUP] 2 [/SUP], Pau Serra[SUP] 2 [/SUP], Edwards Pradenas[SUP] 9 [/SUP], Benjamin Trinité[SUP] 9 [/SUP], Julià Blanco[SUP] 9 10 [/SUP], Alfredo Mayor[SUP] 1 4 5 [/SUP], Sonia Barroso[SUP] 11 [/SUP], Pilar Varela[SUP] 11 [/SUP], Anna Vilella[SUP] 1 5 [/SUP], Antoni Trilla[SUP] 1 5 12 [/SUP], Pere Santamaria[SUP] 7 13 14 [/SUP], Carlo Carolis[SUP] 8 [/SUP], Marta Tortajada[SUP] 11 [/SUP], Luis Izquierdo[SUP] 1 [/SUP], Ana Angulo[SUP] 2 3 [/SUP], Pablo Engel[SUP] 2 3 [/SUP], Alberto L García-Basteiro[SUP] 1 4 15 [/SUP], Gemma Moncunill[SUP] 16 [/SUP], Carlota Dobaño[SUP] 17 18 [/SUP]
Affiliations
- PMID: 34362897
- DOI: 10.1038/s41467-021-24979-9
Abstract
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.